Outcome of Board meeting held on May 30, 2025 Dear Sir/Madam, Pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 12.6 pts less than Nifty Microcap 250 and 12.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Coral Laboratories' Board approved audited standalone financial results for Q4 and FY ended March 31, 2025, with an unmodified opinion from statutory auditors. Full-year revenue from operations grew about 37.5% to ₹11,500.53 lakhs (from ₹8,366.04 lakhs in FY24), while net profit surged roughly 53% to ₹2,415.56 lakhs (from ₹1,578.90 lakhs), pushing EPS to ₹67.61 vs ₹44.19. The Q4 standalone numbers were softer, with revenue at ₹2,813.47 lakhs and profit at ₹282.71 lakhs, partly impacted by an exceptional item of ₹76.96 lakhs towards an earlier-year income tax provision. The Board recommended a 15% final dividend (₹1.50 per share on ₹10 face value), subject to shareholder approval, and appointed Secretarial, Internal, and Cost Auditors for FY26.
Strong full-year revenue and profit growth, a healthy dividend, and positive operating cash flow of ₹733.15 lakhs signal robust business momentum, which is positive for shareholders, though the weaker Q4 print and exceptional charge may temper near-term sentiment slightly.